Cathie Wood sells $16M of surging semiconductor stock thestreet.com

Source: Bloomberg, 5:29

A Michigan summer arts camp and boarding school where Jeffrey Epstein has been accused of meeting at least two of his victims will tear down a lodge that once bore his name. The Interlochen Center for the Arts said this week that its board of trustees has approved a plan to demolish the Green Lake Lodge, which had been known as Jeffrey E Epstein Scholarship Lodge until the school cut ties and scrubbed references to the late millionaire sex offender after his first conviction in 2008. Epstein attended the Interlochen arts camp in 1967 as a teenager, and donated more than $400,000 to the school between 1990 and 2003, including $200,000 for the construction of the lodge. “The lodge has, over time, come to carry associations that are not reflective of who we are as an institution or the values we strive to uphold,” Interlochen said in a statement. “After careful consideration, the board determined that removing this structure in a safe and timely manner is the right step for Interlochen at this time.” A world-renowned destination for young artists, actors and musicians, Interlochen’s alumni include Grammy winners Chappell Roan and Norah Jones and Oscar winner Da’Vine Joy Randolph. At least two of Epstein’s accusers have said they met him at Interlochen in the 1990s. The school said it was aware of news reports about the women’s claims and said it has invited them to speak with an independent investigator as part of an external investigation into reports of historical misconduct at Interlochen. A pair of internal reviews, most recently after Epstein’s sex trafficking arrest in 2019, found no reports of misconduct at Interlochen involving Epstein in its records, the school said. Epstein visited Interlochen periodically, often with his confidante and former girlfriend Ghislaine Maxwell, and stayed in the lodge now marked for demolition. According to correspondence included in the justice department’s recent release of Epstein-related records, he directed that tuition for a...

primeimages/E+ via Getty Images The following segment was excerpted from the Baron Health Care Fund Q1 2026 Shareholder Letter . During the quarter ended March 31, 2026, Baron Health Care Fund® (the Fund)( BHCHX ) declined 6.97% (Institutional Shares), compared with the 4.88% decline for the Russell 3000 Health Care Index (the Benchmark) and the 3.96% decline for the Russell 3000 Index (the Index). Since inception (April 30, 2018), the Fund increased 9.39% on an annualized basis compared with the 8.97% gain for the Benchmark and the 13.26% gain for the Index. Recent Activity During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. Below we discuss some of our top net purchases and sales. Top net purchases for the quarter Quarter End Market Cap($B) Net Amount Purchased ($M) Johnson & Johnson ( JNJ ) 588.8 4.3 Guardant Health, Inc. ( GH ) 12.1 3.5 Natera, Inc. ( NTRA ) 28.3 3.0 Merck & Co., Inc. ( MRK ) 297.4 2.9 BillionToOne, Inc. ( BLLN ) 3.6 1.6 Click to enlarge We increased the position in Johnson & Johnson (J&J), a large-cap health care company with two segments, Innovative Medicine and MedTech. J&J has been actively optimizing its portfolio, separating and spinning off lower-growth and less attractive businesses and investing in higher growth, innovative businesses. This has led to a portfolio of businesses with accelerating growth, which we think justifies a higher multiple. For example, J&J spun off its consumer health business (along with talc-related liabilities) in 2023 into a new, independent company named Kenvue, and in October 2025, J&J announced plans to separate its orthopedics business into a new, independent entity named Depuy Synthes. J&J is now focused on the Innovative Medicine segments (focused on oncology, immunology, and neuroscience) and a growth MedTech business (focused on cardiology, robotic surgery, and vision). Management guidance for 2026 operational sales growth is roughly...

Shares of Sweetgreen (SG +8.15%) were moving higher today even as there was no major news out on the stock. Instead, positive chatter on social media and investor bets that their new wraps would drive a comeback continued to push the stock higher. As of 2:35 p.m. ET, shares were up 9.7%. Are wraps taking off? Sweetgreen stock is now up more than 50% since May 13, even as there's been no major news other than the national launch of four wraps, which are designed to give customers a lower-priced option as Sweetgreen seemed to be suffering from the perception of being overpriced. One person on X said that a manager told her that wraps are making up close to half of the company's orders, a good sign that they are driving growth. The wraps seem to have generally received positive reviews online as well. Additionally, Sweetgreen named Cindy Olsen as its Chief Strategy Officer yesterday, a new position in the company. While the market doesn't typically react to news like that, it does seem like a positive step in its turnaround. Last week, JPMorgan Chase upgraded the stock to overweight after meeting with management, saying that its transformation was gaining momentum in part due to wraps. Expand NYSE : SG Sweetgreen Today's Change ( 8.15 %) $ 0.76 Current Price $ 10.02 Key Data Points Market Cap $1.1B Day's Range $ 9.58 - $ 10.39 52wk Range $ 4.49 - $ 16.70 Volume 321.2K Avg Vol 4.8M Gross Margin 2.52 % What's next for Sweetgreen We won't get an official update from Sweetgreen until its second-quarter report is due out in August. However, the company is scheduled to participate in a fireside chat at a TD Cowen conference next Tuesday, June 2 at 8:00 a.m. ET. The company made that announcement this morning, which also may have excited investors, as it has only done one other analyst conference this year. Investors will likely want to tune in for that presentation as management should provide some color on the performance of its wraps and the overall business. Given the rec...

Meta Platforms Inc Stock (META) Moved Up by 3.10% on May 27: What Signal Does It Send? TradingKey

Shares of semiconductor company Marvell Technology (MRVL) jumped by 6.08% intraday on May 26, after the company received an upgrade from HSBC. Analysts at HSBC lifted Marvell’s rating from “Hold” to “Buy” and raised the price target from $85 to $300 (indicating a 44.1% upside from current levels), citing a “supercycle” related to AI networking. Analyst Frank Lee believes that revenue growth from optical interconnect is still being underestimated by the market, with the technology being potentially an upside driver to consensus forecasts over the next couple of years. In addition, the memory shortage affecting agentic AI CPUs could lead to more upside. The analyst expects Marvell to be a “key beneficiary” as AI clusters mature into AI factories, thereby raising the importance of optical interconnects. At this juncture, we take a closer look at Marvell. About Marvell Technology Stock Marvell Technology is a semiconductor firm that builds data infrastructure chips, including Ethernet switches, optical links, custom AI accelerators, and storage controllers, spanning from the data center core to the network edge. Based in Wilmington, Delaware, Marvell plays a vital role in AI by delivering custom silicon and high-speed optical connectivity that handles the massive data transfer and accelerated computing required by generative AI workloads. Major hyperscalers, including Amazon (AMZN), Microsoft (MSFT), and Alphabet's (GOOG) (GOOGL) Google, rely on Marvell’s bespoke chips and networking technology to power their AI infrastructure, positioning the company as a key enabler of worldwide AI expansion. The company has a market capitalization of $186.88 billion. As Marvell’s business has pivoted decisively to AI data center growth, driven by explosive demand for optical connectivity and Ethernet switches, the stock has gained 212.43% over the past 52 weeks and is up 134.63% year-to-date (YTD). The stock reached a 52-week high of $217.45 on May 26, but is down 7.1% from that leve...

Micron Technology Inc. ’s incredible rally this year has launched the memory-chip firm into an elite group of stocks worth at least $1 trillion, setting at least one record along the way. The stock pushed to another all-time high on Wednesday, gaining as much as 6.7%, adding to its 19% surge from a day prior that catapulted it above the trillion dollar threshold for the first time. The meteoric rise, which includes a gain of more than 186% from its March 30 trough, comes as investors pile into stocks that stand to benefit from soaring demand for memory-related semiconductors, a crucial element for building artificial intelligence infrastructure. Read More: Micron Tops $1 Trillion in Value as UBS Says Stock Could Double The momentum in Micron — and its memory chip peers including Sandisk Corp. , SK Hynix Inc. and Samsung Electronics Co. — comes as companies continue to pledge hundreds of billions of dollars in capital expenditures to AI build outs. That’s put memory components in high demand and potentially broken a pattern of cyclical profits that the sector is known for. Here’s three charts that break down Micron’s meteoric stock gains. It took Micron only 48 trading days to double its market capitalization from $500 billion to $1 trillion, the fastest on record. The rally beat the previous record of 82 days that Samsung had just set earlier this month. Prior to that, Tesla Inc. had held the record since 2021 with a 230 day run between the two milestones. SK Hynix nearly bested the bunch when it hit crested the $1 trillion level Wednesday in South Korea, 61 days after hitting $500 billion in February. Micron is one of the top performing stocks with more than $250 billion in value over the last year. The firm’s shares have gained nearly 850% over the last 12 months, making it the second-best performer among mega-capitalization stocks. Its performance has only lagged South Korean memory peer SK Hynix, which is up more than 1,000%. The tech-heavy Nasdaq 100 Index is u...

Three Charts Capturing Micron’s Record Rise to $1 Trillion Bloomberg.com

临床阶段生物制药公司Atossa Therapeutics， Inc．（ 纳斯达克 代码：ATOS）今日宣布，两篇关于其在研药物（Z）-Endoxifen的摘要已获2026年美国临床肿瘤学会（ASCO）年会收录，该年会将于5月29日至6月2日在芝加哥举行。摘要重点展示了该药物在携带ESR1突变的乳腺癌模型中的抑制活性，以及正在进行的EVANGELINE二期临床试验的最新进展。 第一篇摘要呈现了临床前数据，显示（Z）-Endoxifen能够在携带ESR1突变的乳腺癌模型中抑制雌激素受体信号传导。在MCF-7乳腺癌细胞中，该药物将雌激素受体活性降低至对照组水平的16%至26%。数据表明，该化合物对Y537N、Y537S及D538G三种突变均保持了持续的抑制效果。与口服选择性雌激素受体降解剂elacestrant及imlunestrant相比，（Z）-Endoxifen在ESR1突变环境中显示出更优的抑制效果。 第二篇摘要介绍了EVANGELINE研究，这是一项正在进行的II期临床研究，评估（Z）-Endoxifen每日40毫克联合戈舍瑞林作为新辅助疗法，用于绝经前雌激素受体阳性/HER2阴性乳腺癌女性患者的治疗效果。该研究的主要目标是确定基线Ki-67高于10%的患者中，经过四周治疗后Ki-67降至10%或以下的比例。试验采用Simon两阶段设计，已于2025年5月启动入组。 Atossa总裁兼首席执行官Steven Quay博士表示：“我们的临床前数据表明，（Z）-Endoxifen在与内分泌耐药相关的临床相关ESR1突变中实现了强大的雌激素受体抑制，而EVANGELINE试验正在评估其在绝经前女性新辅助治疗中联合卵巢功能抑制的潜力。这两篇摘要共同强化了我们的信念，即（Z）-Endoxifen有潜力解决ER阳性乳腺癌多个治疗环境中重要的未满足医疗需求”。 责任编辑：张俊 SF065

Key Points Newmont provides massive scale and a diversified portfolio across five continents. SSR Mining offers significant revenue growth and is about to make a big strategic move. Which gold producer fits best in your 2026 portfolio strategy? 10 stocks we like better than Newmont › Should you anchor your portfolio with the world’s largest gold producer or a smaller, high-growth competitor? Choosing between Newmont (NYSE:NEM) and SSR Mining (NASDAQ:SSRM) requires weighing massive scale against operational agility. The case for Newmont Newmont is the largest gold company in the world, maintaining a massive portfolio that includes copper, silver, zinc, and lead. It operates active mines across nine countries, providing diversification through significant assets in Africa, Australia, North America, and beyond. This global footprint makes it a titan among gold stocks, as it manages a workforce of more than 45,000 employees to maintain production levels. In fiscal year 2025, Newmont’s sales rose 21% to $22.7 million, while it reported a net income of $7.1 billion for the period. This performance follows a strong trend, as net income was close to $3.3 billion in FY 2024. As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 0.2x. This ratio measures total debt relative to shareholder equity, indicating that the company uses a conservative amount of borrowed money. The current ratio is roughly 2.3x, which measures the ability to cover short-term debts with assets that can be converted to cash within one year. Free cash flow (FCF) for the year was a massive $7.3 billion, representing the cash remaining after the company pays for its operations and capital investments. The case for SSR Mining SSR Mining operates as an intermediate producer with core mining activities in the U.S., Canada, and Argentina. Core mines include Marigold in Nevada and Puna in Argentina. Customer concentration is high, as sales to Canadian Imperial Bank of Commerce (NYSE:C...

環地中海游泳賽卡內站 何詩蓓100自摘銀 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】環地中海游泳賽卡內站，100米自由泳港隊的何詩蓓奪得銀牌。 初賽游出54秒22，第2名晉級。何詩蓓決賽游第5線，跟上一站冠軍第4線的施甸貝根再次鬥法，兩人早早帶開。完成頭半程，何詩蓓慢這位荷蘭勁敵0.58秒，第二名轉池。最後50米繼續落後大約半個身位，結果連續兩站得第二。這位香港女飛魚比上一站快了0.31秒，游出52秒36。施甸貝根就以51秒86破大會紀錄奪金。第二日賽事何詩蓓將轉戰50、200米自由泳。

临床阶段生物技术公司MetaVia Inc．（ 纳斯达克 代码：MTVA）今日在巴塞罗那举行的欧洲肝脏研究学会（EASL）2026年大会上的重磅壁报环节，公布了其新型双受体激动剂DA-1726在高剂量1期临床试验中的最新数据。结果显示，该药物在减重、缩小腰围及改善肝脏相关指标方面表现出良好潜力。 DA-1726是一种新型的肠调素类似物，可同时靶向胰高血糖素样肽-1受体（GLP1R）和胰高血糖素受体（GCGR）。此次公布的48毫克队列数据显示，在未进行剂量滴定的情况下，肥胖受试者在第54天时平均体重下降达9.1%，且未出现平台期；腰围平均减少9.8厘米。安全性方面，DA-1726总体耐受性良好，未出现严重不良事件或治疗相关停药事件，胃肠道不良事件主要为轻至中度且呈一过性，也未观察到有临床意义的心血管参数变化。 值得注意的是，探索性FibroScan无创肝脏评估显示出早期肝脏相关改善。在第54天时，48毫克组的受控衰减参数（CAP）较基线下降20.0 dB/m，而安慰剂组则上升24.0 dB/m；通过振动控制瞬态弹性成像（VCTE）测量的肝脏硬度值也较基线下降10.3%，安慰剂组则上升13.8%。 MetaVia首席执行官Hyung Heon Kim表示，这些数据进一步强化了DA-1726作为GLP-1/胰高血糖素双受体激动剂的差异化代谢特征，特别是在探索性FibroScan结果中观察到的肝脏生物标志物改善，进一步说明了其在肥胖及相关肝病MASH中的治疗潜力。目前，评估更高剂量和更长治疗时间的1期Part 3a/3b滴定研究正在进行中，预计2026年第四季度公布数据。 责任编辑：张俊 SF065

Meta files WARN notice for 1,395 Washington layoffs starting in July KOMO

Roku just unveiled the biggest overhaul to its smart TV operating system (OS) in 10 years. The most noticeable difference is a new ad space that takes up a large chunk of the screen’s right side. Before the update, loading up a Roku OS-powered smart TV or streaming device would yield a menu on the left side with sections including “What to Watch,” “Live,” and “Search.” The right side had a row of tiles for “Recommended” content above several rows of tiles representing downloaded apps. The old Roku home screen. Credit: Roku The right side of the new Roku OS home screen is dedicated to ads. The ad remains visible as you navigate different parts of the Roku menu, taking away space that could be used for displaying apps and content. Read full article Comments

More people are going hungry now than at the height of the pandemic toggle caption Mark Felix/AFP More people in the United States are going hungry now than during the depths of the pandemic six years ago. A survey released Wednesday by the Federal Reserve Bank of New York found higher levels of food insecurity this year than during the summer of 2020, when the coronavirus outbreak sparked double-digit unemployment. The New York Fed periodically asks Americans if they're having to skip meals, rely on food donations or receiving federal assistance to buy groceries. Replies from the most recent survey in February show hunger is a more pervasive problem now than at any time in the last six years. Sponsor Message Amy Breitmann, who runs the Golden Harvest Food Bank in Augusta, Ga., has witnessed the growing number of families and children in need of food. "We have some distributions where people are sitting in a two- to three-mile line the night before a distribution starts," Breitmann says. "They're sleeping in their cars." The New York Fed survey from February found that nationwide, 10% of families reported missing meals for lack of food, and nearly 16% relied on food donations. Among families earning less than $50,000 a year, rates of food insecurity were about twice as high, with nearly 20% forced to skip meals or go without. Other states also face increasing food insecurity The Community Food Bank of Central Alabama, which serves 12 counties in the state, is moving into a larger building to accommodate the increased need. "Food insecurity could be your next door neighbor," says Nicole Williams, CEO of the food bank. "When gas cost a little bit more or food costs a little bit more, or they have a repair on their car or a medical bill, that takes away what they might be using to spend on food." The results highlight what observers have called a "K-shaped economy", with a growing divide between the haves and have-nots. Sponsor Message "While many households are doing ...

Another surge for Micron, Wall Street’s latest $1 trillion company, sends US stocks to records Idaho News 6

格隆汇5月28日｜Meta Platforms(META.O)涨幅扩大至超4%。

J Studios/DigitalVision via Getty Images Investment Overview My last call on Biohaven Ltd. ( BHVN ) in a note for Seeking Alpha last November was a Hold at $8 per share. However, since that note, Biohaven stock has in fact rallied by >35%, with the stock trading at ~$11 at the time of writing, with a market cap valuation of $1.69bn. Stock is buoyant today - up nearly 10% - as the New Haven, Connecticut-based biotech shared an R&D Day presentation and also shared updates from its proprietary extracellular MoDE™ (BHV-1300) and TRAP™ (BHV-1400) degrader platform. At the time of my last note, Biohaven had shared Q3 2025 earnings and updates, including that it had initiated a strategic cost optimization effort and that it would focus forward-looking spend on three late-stage clinical programs, as follows: Opakalim, Kv7 ion channel activator, in pivotal studies for focal epilepsy and depression; Lead TRAP and MoDE extracellular degraders for IgA nephropathy (BHV-1400) and Graves' disease (BHV-1300); Taldefgrobep alfa, a myostatin-activin pathway inhibitor, for obesity and spinal muscular atrophy. I noted that on a nine-month basis, Biohaven had invested $513m in R&D—down from $628m in 2024—and reported a net loss of $(593m), or $(5.74) per share. I concluded that: 2026 feels like a critical year in which Biohaven must justify the funds invested in R&D, but I would not be especially optimistic. I can't see compelling evidence to support approval of any of the "late-stage" candidates, although in fairness to the company, that could all change this quarter, with the MDD data, let alone next year. With the current cash burn completely unsustainable, it will be interesting to see what happens next—my prediction would be for at least one more asset or target indication to be sidelined next year. Shortly after that note, Biohaven priced a $175m public offering of shares, yet its share price climbed >$10 per share before the company shared its major depressive disorder ("MDD") da...

UBER260821P00087500 互動股市圖表 | UBER Aug 2026 87.500 put 股市 Yahoo 財經

纽约证券交易所集团（NYSE Group）总裁林恩·马丁（Lynn Martin）被《财富》杂志评选为2026年“最具影响力商界女性”（Most Powerful Women in Business）榜单成员。 马丁是纽约证券交易所230多年历史上第68任总裁，也是第二位担任该职位的女性。在她的领导下，纽交所正经历上市环境的强势回暖。数据显示，2025年上半年，纽交所以610亿美元的融资额领跑行业，新股上市、后续发行以及投资者兴趣的回升为市场注入了新的活力。 除了管理交易所，马丁还在纽交所母公司 洲际交易所 （ICE）担任固定收益与数据服务业务主席，该业务始于ICE 2015年对Interactive Data Corp的收购，她在此过程中发挥了关键作用。2025年，马丁还将纽交所品牌拓展至华尔街以外，推出了在得克萨斯州运营的首家证券交易所NYSE Texas。 马丁的影响力已延伸至公司之外。2026年5月，她作为特朗普总统对华国事访问的美国商界代表团成员之一前往北京，随后受白宫邀请赴上海出席APEC 2026第二次高官会及相关会议，并在APEC妇女与经济论坛上就人工智能治理与女性经济机遇发表演讲。她是代表团中仅有的三位女性商界领袖之一。 根据《财富》杂志的信息，本年度榜单涵盖了94家公司的女性领导者，这些公司共拥有1180万名员工，年收入合计达7.3万亿美元。花旗集团首席执行官简·弗雷泽（Jane Fraser）位列榜首， 通用汽车 的玛丽·芭拉（Mary Barra）位居第二。 责任编辑：张俊 SF065

XRP (CRYPTO: XRP) has one of the most loyal followings in crypto. Believers have been waiting years for the token to break out in a meaningful way, and some of them have been burned waiting. But the asset has a history of explosive moves, and the setup today looks different from anything in the past ... Will XRP Ever Skyrocket? What Conditions Would Trigger It

TSCO260626C00032000 互動股市圖表 | TSCO Jun 2026 32.000 call 股市 Yahoo 財經

中性原子量子技术公司Infleqtion（纽约证券交易所代码：INFQ）今日宣布，公司首席执行官Matt Kinsella将于2026年6月2日美国东部时间下午1时出席在旧金山举行的Evercore技术、媒体与电信会议，参与一场炉边谈话。本次会议演讲将通过网络直播，投资者可通过公司官网投资者关系栏目访问。 Infleqtion是一家专注于量子计算、量子网络、量子传感和量子安全的全球技术领导者。公司采用中性原子技术路线，产品组合涵盖量子计算机、量子光钟、射频接收器和惯性传感器，并拥有专有的Superstaq量子计算软件平台。与需要接近绝对零度运行的超导量子比特不同，中性原子在室温环境下即可运行，在扩展性方面具有显著优势。 公司近期获得了一系列重要政府合同与资金支持。2026年5月，Infleqtion与美国商务部签署意向书，拟根据《CHIPS法案》获得1亿美元资金，用于推进中性原子量子系统在美国境内的研发工作。此前，公司还获得了DARPA价值200万美元的合同，用于开发混合量子网络软件，并向国际空间站交付了升级版量子硬件。 根据公司5月发布的首份上市公司财报，2026年第一季度营收达950万美元，同比增长14%，每股亏损从上年同期的41美分收窄至26美分。公司已将2026年全年营收指引上调至至少4000万美元。Infleqtion的技术已被美国国防部、NASA、英国政府采用，并与英伟达保持持续合作，双方共同发布了全球首个使用逻辑量子比特的材料科学应用演示。 责任编辑：张俊 SF065

多區今早錄逾32度 天文台料明極端酷熱 新界或高達37度 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】酷熱天氣警告現正生效。 元朗公園、大埔、西貢、黃大仙等多區早上十時均錄得超過32度。天文台預計今日市區最高氣溫可達34度，新界再高兩三度。天文台提醒市民預防中暑，避免長時間在戶外活動，展望明日日間極端酷熱，新界氣溫最高可達36至37度，會有幾陣驟雨及雷暴。